IDH2 and glioblastoma: This distinction is critical, as IDH-mutant astrocytomas generally have a better prognosis compared to IDH-wildtype GBM, reinforcing the importance of IDH status as a key biomarker for accurate diagnosis and personalized treatment planning [55] (Fig. 8).